Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Lung Cancer - Overview - Disease Synopsis

Drugs & Clinical Candidates


31 drugs have received FDA approval for Lung Cancer . Afatinib Dimaleate, Atezolizumab, Bevacizumab, Brigatinib, CH5424802, Ceritinib, Crizotinib, Dabrafenib, Dacomitinib, Docetaxel, Doxorubicin Hydrochloride, Durvalumab, Erlotinib Hydrochloride, Etoposide, Etoposide Phosphate, Everolimus, Gefitinib, Gemcitabine Hydrochloride, Lorlatinib, Methotrexate Sodium, Necitumumab, Nivolumab, OSIMERTINIB MESYLATE, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Ramucirumab, Sodium, Topotecan Hydrochloride, Trametinib and Vinorelbine Tartrate
524 drugs have a clinical trial registered for Lung Cancer.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 4766 clinical trials for Lung Cancer,
2993 of which have one or more drug interventions,
1773 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 2032 Cell Line Models for Lung Cancer.

Source: COSMIC
(see details)

Chemistry


There are 13817 Compounds which have been tested in Lung Cancer , 8334 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Lung Cancer:
Adenocarcinoma of Lung
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Small Cell Lung Carcinoma

The following terms have been mapped from cancer.gov to Lung Cancer:
Hepatic veno-occlusive disease (also known as sinusoidal obstruction syndrome) in adults and children who also have kidney or lung problems after receiving a stem cell transplant
In patients with squamous NSCLC that got worse after treatment with platinum chemotherapy
Lung cancer
Non-small cell lung cancer
Non-small cell lung cancer that has metastasized. It is used:With pemetrexed and platinum chemotherapy as first-line treatment in patients with nonsquamous disease that does not have a mutation in the EGFR gene or ALK gene
Non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It is used as first-line treatment in patients whose tumors have certain EGFR gene mutations
Non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It is used as first-line treatment in patients whose tumors have certain EGFR gene mutations
Non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It is used:As first-line treatment in patients with tumors that have certain EGFR gene mutations
Non-small cell lung cancer (NSCLC) that is metastatic and has certain EGFR gene mutations. It may be used:As first-line therapy
Non-small cell lung cancer (NSCLC). It is used in patients with stage III NSCLC that cannot be removed by surgery and did not get worse after platinum chemotherapy and radiation therapy
Non-small cell lung cancer (certain types) in patients whose disease is locally advanced or has metastasized (spread to other parts of the body)
Non-small cell lung cancer in certain patients whose cancer is locally advanced or has metastasized
Non-small cell lung cancer in patients whose disease is locally advanced or has metastasized (spread to other parts of the body).
Non-small cell lung cancer that is anaplastic lymphoma kinase (ALK) positive and has metastasized (spread to other parts of the body). It is used in patients whose disease got worse after treatment with:Crizotinib and at least one other ALK inhibitor therapy for metastatic disease, or
Non-small cell lung cancer that has metastasized (spread to other parts of the body). It is used in patients whose tumors have certain EGFR gene mutations either as first-line treatment or for disease that got worse during or after treatment with another EGFR tyrosine kinase inhibitor
Non-small cell lung cancer that has metastasized. It is used in patients whose disease got worse during or after treatment with platinum chemotherapy. Patients whose cancer has certain gene mutations should receive nivolumab only if their disease got worse after treatment with FDA-approved therapy for the gene mutations
Non-small cell lung cancer that has metastasized. It is used with dabrafenib
Non-small cell lung cancer that has metastasized. It is used with docetaxel in patients whose disease has gotten worse after treatment with platinum chemotherapy. For patients whose cancer has a mutation in the EGFR gene or ALK gene, ramucirumab is used if their disease has gotten worse after treatment with FDA-approved therapy for these mutations
Non-small cell lung cancer that has metastasized. It is used with trametinib
Non-small cell lung cancer that has metastasized. It is used:In adults whose disease has gotten worse during or after treatment with platinum chemotherapy. For patients whose cancer has a mutation in the EGFR gene or ALK gene, atezolizumab is used if their disease has gotten worse after treatment with FDA-approved therapy for these mutations
Non-small cell lung cancer that is anaplastic lymphoma kinase (ALK) positive and has metastasized (spread to other parts of the body)
Non-small cell lung cancer that is advanced or has metastasized. It is used in patients whose disease cannot be removed by surgery. It is used with cisplatin
Non-small cell lung cancer that is anaplastic lymphoma kinase (ALK) positive and has metastasized (spread to other parts of the body)
Non-small cell lung cancer that is anaplastic lymphoma kinase (ALK) positive and has metastasized (spread to other parts of the body). Brigatinib is used in patients whose cancer cannot be treated with crizotinib or got worse while taking crizotinib
Non-small cell lung cancer that is anaplastic lymphoma kinase (ALK) positive or ROS1 positive and has metastasized (spread to other parts of the body)
Non-small cell lung cancer that is locally advanced or has metastasized and cannot be treated with surgery or radiation therapy. It is used with carboplatin
Nonsquamous non-small cell lung cancer that is locally advanced, cannot be removed by surgery, has metastasized, or has recurred
Pancreatic cancer, gastrointestinal cancer, and lung cancer (certain types). It is used in adults with progressive neuroendocrine tumors that cannot be removed by surgery, are locally advanced, or have metastasized (spread to other parts of the body)
Small cell lung cancer
Small cell lung cancer in patients whose disease has not gotten better with other chemotherapy
Small cell lung cancer that has metastasized. It is used in patients whose disease got worse after treatment with platinum chemotherapy and at least one other therapy
Small cell lung cancer. It is used with carboplatin and etoposide as first-line therapy in adults with extensive-stage disease
Squamous non-small cell lung cancer that has metastasized (spread to other parts of the body). It is used as first-line treatment